

Table 4.2
Counts (Annualized Percentages) of Participants with Self-Reported Outcomes by Race/Ethnicity for
MRC Super Cohort Participants¹ Who Did Not Report a Prevalent Condition at Baseline

Data as of: February 19, 2022; Events through February 19, 2022

Outcomes	Race/Ethnicity						
	American Indian/ Alaska Native	Asian or Native Hawaiian/ Other Pacific Islander ²	Hispanic/ Latina	Non-Hispanic Black/African American	Non-Hispanic White	More than one Race	Other/Not Reported
Number of participants	108	526	6525	14025	22278	550	162
Mean follow-up (months)	171.6	182.6	164.3	172.1	207.8	211.4	167.5
Angina (hospitalized) ³	12 (0.82%)	25 (0.33%)	382 (0.45%)	1052 (0.56%)	2092 (0.57%)	62 (0.69%)	11 (0.51%)
Diabetes (treated)	18 (1.43%)	102 (1.35%)	1208 (1.44%)	2901 (1.60%)	3969 (1.07%)	122 (1.39%)	34 (1.58%)
Hysterectomy	4 (0.50%)	14 (0.25%)	295 (0.59%)	439 (0.49%)	1170 (0.47%)	18 (0.39%)	2 (0.16%)
Osteoarthritis ⁴	30 (3.56%)	179 (3.15%)	2145 (3.58%)	4020 (3.33%)	7574 (3.09%)	192 (3.50%)	54 (3.71%)
Intestinal polyps	26 (1.80%)	109 (1.50%)	1360 (1.61%)	3459 (1.86%)	5729 (1.60%)	167 (1.86%)	33 (1.53%)
Lupus ⁴	1 (0.07%)	4 (0.05%)	132 (0.16%)	280 (0.15%)	378 (0.10%)	15 (0.16%)	1 (0.05%)
Hypertension treated w/pills	49 (4.85%)	199 (3.61%)	2429 (3.59%)	4251 (4.14%)	9572 (3.30%)	241 (3.79%)	48 (3.53%)
COPD ⁵	6 (0.67%)	20 (0.43%)	282 (0.48%)	717 (0.59%)	1820 (0.96%)	45 (0.97%)	7 (0.49%)
Macular degeneration ⁶	12 (0.91%)	43 (0.74%)	604 (0.78%)	983 (0.60%)	3866 (1.45%)	76 (1.18%)	18 (0.91%)
Dementia ⁶	8 (0.61%)	60 (1.03%)	647 (0.84%)	1352 (0.82%)	3662 (1.37%)	89 (1.38%)	19 (0.96%)
Parkinson's disease ⁶	2 (0.15%)	8 (0.14%)	81 (0.10%)	155 (0.09%)	416 (0.16%)	9 (0.14%)	2 (0.10%)

¹ The MRC Super Cohort includes all WHI Hormone Trial participants and all Non-Hispanic Black/African American and Hispanic/Latina participants (identified from race/ethnicity collected on Form 2 at baseline) from the CT and OS. However, race/ethnicity is presented using the imputed Form 41 data and following the WHI Race/Ethnicity Task Force guidelines.

² Native Hawaiian/Other Pacific Islander MRC Super Cohort participants (n=40) are combined with Asian MRC Super Cohort participants for reporting purposes due to small numbers.

³ During WHI Extension Study 2005-2010, the outcome was angina with hospitalization for a heart condition that may or may not have been related to the angina.

⁴ This outcome has not been self-reported on all versions of Form 33 during WHI follow-up. The annualized percentages are corrected for the different amounts of follow-up.

⁵ Data only collected during the WHI Extension Study 2010-2025.

⁶ Data only collected during the WHI Extension Studies 2005-2025.